These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 23508652

  • 1. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS.
    Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
    [Abstract] [Full Text] [Related]

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 3. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar 17; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.
    Blair NF, Brew BJ, Halpern JP.
    Neurology; 2012 Feb 14; 78(7):507-8. PubMed ID: 22302545
    [No Abstract] [Full Text] [Related]

  • 5. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.
    Mult Scler; 2013 Dec 14; 19(14):1826-40. PubMed ID: 24192217
    [Abstract] [Full Text] [Related]

  • 6. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.
    Arch Neurol; 2010 Nov 14; 67(11):1391-4. PubMed ID: 20625069
    [Abstract] [Full Text] [Related]

  • 7. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.
    Phan-Ba R, Lommers E, Tshibanda L, Calay P, Dubois B, Moonen G, Clifford D, Belachew S.
    J Neurol Neurosurg Psychiatry; 2012 Feb 14; 83(2):224-6. PubMed ID: 22013244
    [Abstract] [Full Text] [Related]

  • 8. JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment.
    Schippling S, Kempf C, Büchele F, Jelcic I, Bozinov O, Bont A, Linnebank M, Sospedra M, Weller M, Budka H, Martin R.
    Ann Neurol; 2013 Oct 14; 74(4):622-6. PubMed ID: 23868420
    [Abstract] [Full Text] [Related]

  • 9. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC.
    Neurology; 2013 Oct 15; 81(16):1400-8. PubMed ID: 24049136
    [Abstract] [Full Text] [Related]

  • 10. The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
    Baheerathan A, McNamara C, Kalam S, Rane N, Barwick TD, Grote H, Nicholas R.
    Neurology; 2018 Sep 18; 91(12):572-573. PubMed ID: 30224501
    [No Abstract] [Full Text] [Related]

  • 11. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T.
    J Neuropathol Exp Neurol; 2012 Jul 18; 71(7):604-17. PubMed ID: 22710964
    [Abstract] [Full Text] [Related]

  • 12. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.
    J Neuroimaging; 2014 Jul 18; 24(4):425-8. PubMed ID: 23323645
    [Abstract] [Full Text] [Related]

  • 13. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
    Metz I, Radue EW, Oterino A, Kümpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, Häusler D, Brück W.
    Acta Neuropathol; 2012 Feb 18; 123(2):235-45. PubMed ID: 22057786
    [Abstract] [Full Text] [Related]

  • 14. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ.
    Neurology; 2012 May 01; 78(18):1390-3. PubMed ID: 22517104
    [Abstract] [Full Text] [Related]

  • 15. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
    Wattjes MP, Verhoeff L, Zentjens W, Killestein J, van Munster ET, Barkhof F, van Eijk JJ.
    J Neurol Neurosurg Psychiatry; 2013 Oct 01; 84(10):1176-7. PubMed ID: 23695498
    [No Abstract] [Full Text] [Related]

  • 16. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 01; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 17. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.
    N Engl J Med; 2005 Jul 28; 353(4):375-81. PubMed ID: 15947078
    [Abstract] [Full Text] [Related]

  • 18. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
    Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, Ryschkewitsch C, Jensen P, Lippmann K, Hemmer B, Major E, Hohlfeld R.
    Mult Scler; 2013 Aug 28; 19(9):1213-5. PubMed ID: 23124790
    [Abstract] [Full Text] [Related]

  • 19. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
    Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, Schulz R, Bofill-Mas S, Jones L, Demina V, Linnebank M, Ogg G, Girones R, Weber T, Sospedra M, Martin R.
    Brain; 2011 Sep 28; 134(Pt 9):2687-702. PubMed ID: 21908874
    [Abstract] [Full Text] [Related]

  • 20. Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy.
    Calvi A, De Riz M, Pietroboni AM, Ghezzi L, Maltese V, Arighi A, Fumagalli GG, Jacini F, Donelli C, Comi G, Galimberti D, Scarpini E.
    Immunotherapy; 2014 Sep 28; 6(1):23-8. PubMed ID: 24341880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.